METIS TECHBIO-P (07666) made its market debut today. According to the company's announcement, the shares were priced at HKD 10.5 each. A total of 201 million shares were issued, with a board lot size of 500 shares. The net proceeds from the offering amount to approximately HKD 1.993 billion. At the time of writing, the stock price has surged by 175.05%, currently trading at HKD 28.88, with a turnover of HKD 1.390 billion.

The prospectus indicates that METIS TECHBIO is an AI-driven nanomaterial innovation company focused on the delivery and application of payloads within various biological systems. The company's core platform, NanoForge, integrates an extensive lipid library, foundational AI models, the METiS intelligent agent, quantum chemistry and molecular dynamics simulations, and an AI-driven high-throughput screening platform. Building on this foundation, the company has developed three major solutions: AiTEM, AiLNP, and AiRNA, which are used for the design, optimization, and validation of advanced nanomaterials and related payloads.

In terms of its pipeline, METIS TECHBIO has over 10 products in development, targeting areas including central nervous system disorders, oncology, immunology, and metabolic diseases. Among these, MTS-004 is the company's most advanced candidate. Public information shows that this product is intended for the treatment of pseudobulbar affect and has already met the primary endpoint in its Phase III clinical study. The company is also advancing commercial validation through product licensing and platform collaborations.